register

Digital & Innovation

TGA launches new regulation for software-based medical devices

Health Industry Hub | February 22, 2021 |
[Total: 1    Average: 4/5]

Software is changing how clinicians practice medicine, how individuals manage their own health and how patients interact with their healthcare providers.

From 25 February 2021, the way that software-based medical devices (SaMD) are regulated in Australia will change.

According to the TGA, rapid innovation in technology has driven significant changes to software function and adoption, giving rise to a larger number of devices able to inform, drive or replace clinical decisions, or directly provide therapy to an individual. Access to software has become much easier, with personal devices including smartphones, wearables and tablets becoming ubiquitous, and improvements to network technology providing increased connectivity via technologies such as Bluetooth and WiFi.

The regulatory changes follow an extensive consultation and revision process, which was delayed by the COVID-19 pandemic. Many of the 48 companies who made submissions during the consultation process indicated that where products impact patient safety and public health safety, these should not have reduced regulatory oversight unless risks are well understood by the users. Patients and clinicians who use the software based medical devices, including apps, must be able to trust the efficacy and accuracy and this needs to be assessed by a trusted entity, independent of the software developers.

The changes will include:

  • clarifying the boundary of regulated software products (including ‘carve outs’)
  • introducing new classification rules
  • providing updates to the essential principles to more clearly express the requirements for software-based medical devices.

The new rules provide that all SaMD products will be classified according to intended purpose (diagnosis, screening, monitoring, providing therapy) and the level of risk to the individual or public health.

The new classification rules will apply to all new applications for inclusion in the Australian Register of Therapeutic Goods (ARTG) made on or after 25 February 2021.

Transitional arrangements will apply to devices which are currently included in the ARTG, or which are the subject of an application lodged before 25 February 2021, and would receive a higher classification under the new rules. Such products may continue to be supplied during the transition period under their existing classification as long as the TGA is notified by 25 August 2021. The transition period will end on 1 November 2024.

More information can be found at Regulatory changes for software based medical devices.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Pharmaceuticals

Pharma News - AbbVie, MSD, Genentech and Takeda rank in the top 20 Best Workplaces in Healthcare & Biopharma

AbbVie, MSD, Genentech and Takeda rank in the top 20 Best Workplaces in Healthcare & Biopharma

Health Industry Hub | April 13, 2021 |

Human Resources: AbbVie, MSD, Genentech and Takeda ranked in the top 20 list on the Fortune and Great Place to […]

More


News & Trends - Medical Technology

MedTech News - Philips installs leading digital imaging solutions at the new Westmead Health Precinct

Philips installs leading digital imaging solutions at the new Westmead Health Precinct

Health Industry Hub | April 13, 2021 |

MedTech News: Royal Philips announced the successful installation of the most advanced digital diagnostic and neurovascular imaging solutions supporting the […]

More


News & Trends - Pharmaceuticals

Pharma News - TGA approves Astellas' Xtandi for metastatic hormone-sensitive prostate cancer

TGA approves Astellas’ drug for metastatic hormone-sensitive prostate cancer

Health Industry Hub | April 13, 2021 |

Pharma News: Astellas Pharma announced the Therapeutic Goods Administration (TGA) approval of its oral once-daily therapy for patients with metastatic […]

More


News & Trends - Biotechnology

Biotech News - Roche, Thermo Fisher, Illumina cancer DNA tests validated as an alternative to invasive tissue biopsies

Roche, Thermo Fisher, Illumina cancer DNA tests validated as an alternative to invasive tissue biopsies

Health Industry Hub | April 13, 2021 |

Biotech News: An international team reports the findings of an independent assessment of five commercially-available assays for tumour DNA sequencing […]

More